64Cu-DOTA-anti-CTLA-4 mAb enabled PET visualization of CTLA-4 on the T-cell infiltrating tumor tissues

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Higashikawa, Kei ^a,b   Yagi, Katsuharu ^a   Watanabe, Keiko ^a   Kamino, Shinichiro ^c   Ueda, Masashi ^a   Hiromura, Makoto ^c   Enomoto, Shuichi ^a,c  

^a OKAYAMA UNIVERSITY   (Japan)

^b JAPAN SOCIETY FOR THE PROMOTION OF SCIENCE   (Japan)

^c RIKEN   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY TETRAXETAN COPPER CU 64; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; COPPER; MONOCLONAL ANTIBODY; ORGANOMETALLIC COMPOUND; PROTEIN BINDING;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CANCER TISSUE; COLON MUCOSA; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG STRUCTURE; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTIC INFILTRATION; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR IMAGING; MOUSE; NONHUMAN; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; ANIMAL; ANTAGONISTS AND INHIBITORS; DIAGNOSTIC USE; DISEASE MODEL; GENE EXPRESSION; GENETICS; METABOLISM; NEOPLASMS; PROCEDURES; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; COPPER RADIOISOTOPES; CTLA-4 ANTIGEN; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; NEOPLASMS; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; RADIOPHARMACEUTICALS;

EID: 84909592377     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0109866     Document Type: Article

References (36)

1. Yaguchi T, Sumimoto H, Kudo-Saito C, Tsukamoto N, Ueda R, et al. (2011) The mechanisms of cancer immunoescape and development of overcoming strategies. Int J Hematol 93: 294-300.
2. Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12: 252-264.
3. Grosso JF, Jure-Kunkel MN (2013) CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun 13: 5.
4. Contardi E, Palmisano GL, Tazzari PL, Martelli AM, Fala F, et al. (2005) CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction. Int J Cancer 117: 538-550.
5. Lesterhuis WJ, Haanen JBAG, Punt CJA (2011) Cancer immunotherapy-revisited. Nat Rev Drug Discov 10: 591-600.
6. Ribas A, Hanson DC, Noe DA, Millham R, Guyot DJ, et al. (2007) Tremelimumab (CP-675,206), a cytotoxic T lymphocyte-associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer. Oncologist 12: 873-883.
7. Torino F, Barnabei A, De Vecchis L, Salvatori R, Corsello SM (2012) Hypophysitis induced by monoclonal antibodies to cytotoxic T lymphocyte antigen 4: challenges from a new cause of a rare disease. Oncologist 17: 525-535.
8. Weber JS, Kahler KC, Hauschild A (2012) Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30: 2691-2697.
9. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, et al. (2006) Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355: 1018-1028.
10. Walker LSK, Sansom DM (2011) The emerging role of CTLA4 as a cellextrinsic regulator of T cell responses. Nat Rev Immunol 11: 852-863.
11. Sondak VK, Smalley KS, Kudchadkar R, Grippon S, Kirkpatrick P (2011) Ipilimumab. Nat Rev Drug Discov 10: 411-412.
12. Dijkers EC, Oude Munnink TH, Kosterink JG, Brouwers AH, Jager PL, et al. (2010) Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther 87: 586-592.
13. ClinicalTrials.gov website. Available: http://clinicaltrials.gov/ct2/show/ NCT00605397. Accessed 2014 Sep 20.
14. ClinicalTrials.gov website. Available: http://clinicaltrials.gov/ct2/show/ NCT00474578. Accessed 2014 Sep 20.
15. Cai WB, Chen K, He LN, Cao QH, Koong A, et al. (2007) Quantitative PET of EGFR expression in xenograft-bearing mice using Cu-64-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging 34: 850-858.
16. Niu G, Li Z, Xie J, Le QT, Chen X (2009) PET of EGFR antibody distribution in head and neck squamous cell carcinoma models. J Nucl Med 50: 1116-1123.
17. Bhattacharyya S, Kurdziel K, Wei L, Riffle L, Kaur G, et al. (2013) Zirconium-89 labeled panitumumab: a potential immuno-PET probe for HER1-expressing carcinomas. Nucl Med Biol 40: 451-457.
18. ClinicalTrials.gov website. Available: http://clinicaltrials.gov/show/ NCT00691548. Accessed 2014 Sep 20.
19. Paudyal B, Paudyal P, Oriuchi N, Hanaoka H, Tominaga H, et al. (2011) Positron emission tomography imaging and biodistribution of vascular endothelial growth factor with 64Cu-labeled bevacizumab in colorectal cancer xenografts. Cancer Sci 102: 117-121.
20. Nagengast WB, de Korte MA, Oude Munnink TH, Timmer-Bosscha H, den Dunnen WF, et al. (2010) 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. J Nucl Med 51: 761-767.
21. Higashikawa K, Akada N, Yagi K, Watanabe K, Kamino S, et al. (2011) Exploration of target molecules for molecular imaging of inflammatory bowel disease. Biochem Biophys Res Commun 410(3): 416-21.
22. Lu SX, Takach EJ, Solomon M, Zhu Q, Law SJ, et al. (2005) Mass spectral analyses of labile DOTA-NHS and heterogeneity determination of DOTA or DM1 conjugated anti-PSMA antibody for prostate cancer therapy. J Pharm Sci 94: 788-797.
23. Sakaguchi S, Miyara M, Costantino CM, Hafler DA (2010) FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 10: 490-500.
24. Yamaguchi T, Hirota K, Nagahama K, Ohkawa K, Takahashi T, et al. (2007) Control of immune responses by antigen-specific regulatory T cells expressing the folate receptor. Immunity 27: 145-159.
25. Simms PE, Ellis TM (1996) Utility of flow cytometric detection of CD69 expression as a rapid method for determining poly-and oligoclonal lymphocyte activation. Clin Diagn Lab Immunol 3: 301-304.
26. Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, et al. (2009) Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev 229: 152-172.
27. Selby MJ, Engelhardt JJ, Quigley M, Henning KA, Chen T, et al. (2013) Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells. Cancer Immunol Res 1: 32-42.
28. Mitsui J, Nishikawa H, Muraoka D, Wang L, Noguchi T, et al. (2010) Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals. Clin Cancer Res 16: 2781-2791.
29. Teft WA, Kirchhof MG, Madrenas J (2006) A molecular perspective of CTLA-4 function. Annu Rev Immunol 24: 65-97.
30. Ueda H, Howson JM, Esposito L, Heward J, Snook H, et al. (2003) Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423: 506-511.
31. Vijayakrishnan L, Slavik JM, Illes Z, Greenwald RJ, Rainbow D, et al. (2004) An autoimmune disease-associated CTLA-4 splice variant lacking the B7 binding domain signals negatively in T cells. Immunity 20: 563-575.
32. Araki M, Chung D, Liu S, Rainbow DB, Chamberlain G, et al. (2009) Genetic Evidence That the Differential Expression of the Ligand-Independent Isoform of CTLA-4 Is the Molecular Basis of the Idd5.1 Type 1 Diabetes Region in Nonobese Diabetic Mice. J Immunol 183: 5146-5157.
33. Liu SM, Sutherland APR, Zhang Z, Rainbow DB, Quintana FJ, et al. (2012) Overexpression of the CTLA-4 Isoform Lacking Exons 2 and 3 Causes Autoimmunity. J Immunol 188: 155-162.
34. Gerold KD, Zheng PL, Rainbow DB, Zernecke A, Wicker LS, et al. (2011) The Soluble CTLA-4 Splice Variant Protects From Type 1 Diabetes and Potentiates Regulatory T-Cell Function. Diabetes 60: 1955-1963.
35. Valzasina B, Piconese S, Guiducci C, Colombo MP (2006) Tumor-induced expansion of regulatory T cells by conversion of CD4(+)CD25(2) lymphocytes is thymus and proliferation independent. Cancer Res 66: 4488-4495.
36. Knowles SM, Wu AM (2012) Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology. J Clin Oncol 30: 3884-3892.